華西股份(000936.SZ):上海啓瀾擬將其持有6549.65萬股索爾思光電股份轉讓給超毅集團
格隆匯6月13日丨華西股份(000936.SZ)公佈,近日,上海啓瀾等14家主體擬與超毅集團(香港)有限公司(以下簡稱“股權受讓方”)、蘇州東山精密製造股份有限公司(以下簡稱“東山精密”,股票代碼:002384,與股權受讓方合稱“收購方”)簽署《關於
Source Photonics Holdings(Cayman) Limited
之股份轉讓協議》(以下簡稱“《股份轉讓協議》”),上海啓瀾擬將其持有6,549.65萬股索爾思光電股份轉讓給超毅集團(香港)有限公司,轉讓總價款爲20,026.86萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.